Drug Profile
Difelikefalin - Cara Therapeutics
Alternative Names: CKD-943; CR-845; CR845/difelikefalin; Difelikefalin acetate - Cara Therapeutics; FE-202845; Kapruvia; KORSUVA; Korsuva; MR13A9Latest Information Update: 28 Feb 2024
Price :
$50
*
At a glance
- Originator Ferring Pharmaceuticals
- Developer Cara Therapeutics; Chong Kun Dang; CSL Vifor; Kissei Pharmaceutical; Maruishi Pharmaceutical; Vifor Fresenius Medical Care Renal Pharma
- Class Amines; Analgesics; Antipruritics; Carboxylic acids; Opioid analgesics; Peptides; Piperidines; Skin disorder therapies; Urologics
- Mechanism of Action Opioid kappa receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Pain; Postoperative pain
Highest Development Phases
- Marketed Pruritus
- Phase III Pain; Postoperative pain
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for clinical-Phase-Unknown development in Pain in USA (IV)
- 28 Feb 2024 No recent reports of development identified for phase-I development in Pain in Japan (IV)
- 22 Jan 2024 Cara Therapeutics terminates phase-III KICK 1 trial in Pruritus (Treatment-experienced in USA (PO), as company wants to discontinue the phase III programme (NCT05342623)